Acrivon Therapeutics
IPO
Precision oncology powered by proteomics
- Headquarters
- Watertown, Massachusetts
- Employees
- 51–200
- Founded
- 2018
- Business Model
- B2B
- Website
- acrivon.com
- Total Funding
- $230.0M
- Last Round
- $130.0M Venture RoundApr 2024
About
Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing precision oncology medicines utilizing its proprietary Acrivon Precision Predictive Proteomics (AP3) platform. The AP3 platform enables unprecedented patient selection by profiling the activity of key cancer-driving proteins at the individual tumor level, identifying which patients are most likely to respond to a given targeted therapy. Headquartered in Watertown, Massachusetts, Acrivon is advancing a pipeline of precision oncology drug candidates, including ACR-368, a CHK1/2 inhibitor being evaluated in endometrial and ovarian cancers.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account